HC Wainwright Increases Femasys (NASDAQ:FEMY) Price Target to $15.00

Femasys (NASDAQ:FEMY) had its target price hoisted by stock analysts at HC Wainwright from $12.00 to $15.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Femasys Stock Performance

Femasys stock traded up $0.04 during mid-day trading on Wednesday, reaching $1.58. 371,559 shares of the company’s stock were exchanged, compared to its average volume of 264,004. The business’s fifty day simple moving average is $1.34 and its 200 day simple moving average is $1.20. The company has a quick ratio of 3.26, a current ratio of 3.94 and a debt-to-equity ratio of 0.86. Femasys has a one year low of $0.86 and a one year high of $2.07. The firm has a market capitalization of $36.18 million, a PE ratio of -1.98 and a beta of -2.85.

Institutional Trading of Femasys

A number of large investors have recently added to or reduced their stakes in FEMY. Virtu Financial LLC purchased a new position in Femasys in the fourth quarter valued at about $25,000. Jane Street Group LLC bought a new stake in shares of Femasys in the 4th quarter worth approximately $30,000. XTX Topco Ltd lifted its stake in Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares during the last quarter. Citadel Advisors LLC bought a new position in Femasys during the fourth quarter valued at $45,000. Finally, Northern Trust Corp increased its position in Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after buying an additional 37,675 shares during the last quarter. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.